TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ TXMD opened at $1.53 on Wednesday. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07. The stock’s 50-day moving average price is $1.71 and its two-hundred day moving average price is $1.86.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.